Evidence map›Paper›PMID 41659651›Full record

ArticlebioRxiv : the preprint server for biology2026

D-Methionine Improves Spatial Navigation and Attenuates Oxidative Stress and Amyloid Pathology in a Sex-Specific Manner.

Mackenzie R Peck, Jenelle E Chapman, Tiarra Hill, Kathleen Quinn, Erol D Ikiz, Angel Lopez, Erin R Hascup, Chilman Bae, Kevin N Hascup

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mackenzie R PeckDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Jenelle E ChapmanDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Tiarra HillDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Kathleen QuinnDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Erol D IkizDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Angel LopezDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Erin R HascupDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.ORCID 0000-0003-1037-0809
Chilman BaeSchool of Electrical, Computer, and Biomedical Engineering, Southern Illinois University Carbondale, Carbondale, IL, USA.
Kevin N HascupDale and Deborah Smith Center for Alzheimer's Research and Treatment, Neurosciences Institute, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA.ORCID 0000-0001-6604-1874

Funding

Sequelae of SARS-CoV-2 Infection in Alzheimer's DiseaseR01AG061937 · NIA · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI HASCUP, ERIN R · 2018 to 2022
$4.0M
Glutamate neurotransmission in Alzheimer's disease progressionR01AG057767 · NIA · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI HASCUP, ERIN R · 2018 to 2022
$3.2M
NIA NIH HHS R01 AG057767NIA NIH HHS R01 AG061937
6 · The paper itself

Abstract

Background: Oxidative stress and maladaptive neuroimmune activation contribute to cognitive decline in Alzheimer's disease (AD) and represent therapeutic targets beyond amyloid-centered approaches. Objective: To determine whether oral D-methionine (D-Met), a redox-active amino acid, reduces amyloid pathology and lipid peroxidation and confers disease-modifying benefits in AD mouse models. Methods: Male and female APP/PS1 and APP Results: D-Met did not alter locomotor or exploratory behavior but improved spatial memory recall in both sexes of APP/PS1 mice and in female APP Conclusion: Short-term D-Met acts as a metabolic and redox modulator with modest amyloid-lowering effects mediated by improved microglial function. Therapeutic efficacy is strongly sex- and model-dependent, with the greatest benefit observed in female APP

Indexed as

Alzheimer’s diseaseinflammationmicrogliaoxidative stressPiezo1 mechanosensitive channelwhite adipose tissue

Identifiers

PMID41659651
PMCPMC12873899

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.